IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease
Zhou, Junhua; Zhang, Yimiao; Liu, Gang; Li, Jun; Xu, Rong; Huang, Jing
关键词leflunomide minimal change disease nephrotic syndrome steroid-dependent steroid-resistant
刊名CLINICAL NEPHROLOGY
2013-08-01
DOI10.5414/CN107723
80期:2页:121-129
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Urology & Nephrology
研究领域[WOS]Urology & Nephrology
关键词[WOS]CHANGE NEPHROTIC SYNDROME ; MYCOPHENOLATE-MOFETIL ; RITUXIMAB THERAPY ; CYCLOSPORINE ; NEPHROPATHY ; TRIAL
英文摘要

Objective: To observe the efficacy and safety of leflunomide combined with prednisone therapy (LEF therapy) in the treatment of patients with adult onset steroid-dependent and steroid-resistant minimal change disease (MCD). Methods: 16 MCD patients who had been treated with LEF therapy were retrospectively analyzed. 87.5% (14/16) of the patients were steroid-dependent and 12.5% (2/16) of the patients were steroid-resistant. The initial dose of LEF was 10 - 20 mg/day combined with prednisone 0.25 - 1.0 mg/kg/day, gradually tapering after 8 weeks. Clinical and laboratory data at baseline, 2nd, 4th, 8th, 12th, 24th, and 48th week were analyzed compared with initial course of prednisone monotherapy (FRED monotherapy) and cyclophosphamide combined with prednisone therapy (CTX therapy). Results: All the 16 patients achieved different levels of remission in LEF therapy. 93.8% (15/16) of the patients, including the two steroid-resistant patients, achieved complete remission. During the treatment, 8 patients had adverse effects which could be well tolerated. Compared LEF therapy with PRED monotherapy (n = 16), the dose of prednisone to maintain remission was reduced (from median 22.5 mg/day to median 7.5 mg/day, p = 0.041); relapse rate during the follow-up decreased from 100% to 31.3% (p = 0.002); the median time before relapse increased from 20.3 weeks to 32.5 weeks. Compared LEF therapy with CTX therapy (n = 12), the dose of prednisone to maintain remission was reduced significantly (from median 22.5 mg/day to median 5.0 mg/day, p = 0.003); relapse rate during the follow-up decreased from 100% to 31.3% (p = 0.001); the median time before relapse increased from 11.7 weeks to 32.5 weeks. Conclusions: LEF therapy seems to be effective in steroid-resistant and steroid-dependent MCD. This therapy may reduce the amount of preclnisone to maintain remission and reduce the relapse rate compared with PRED monotherapy and CTX therapy. LEF therapy was usually well tolerated.

语种英语
WOS记录号WOS:000323990000006
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60971
Collection北京大学第一临床医学院
作者单位Peking Univ, Hosp 1, Minist Hlth China, Renal Div,Dept Med,Inst Nephrol,Key Lab Renal Dis, Beijing 100034, Peoples R China
Recommended Citation
GB/T 7714
Zhou, Junhua,Zhang, Yimiao,Liu, Gang,et al. Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease[J]. CLINICAL NEPHROLOGY,2013,80(2):121-129.
APA Zhou, Junhua,Zhang, Yimiao,Liu, Gang,Li, Jun,Xu, Rong,&Huang, Jing.(2013).Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease.CLINICAL NEPHROLOGY,80(2),121-129.
MLA Zhou, Junhua,et al."Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease".CLINICAL NEPHROLOGY 80.2(2013):121-129.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Zhou, Junhua]'s Articles
[Zhang, Yimiao]'s Articles
[Liu, Gang]'s Articles
百度学术
百度学术Similar articles in
[Zhou, Junhua]'s Articles
[Zhang, Yimiao]'s Articles
[Liu, Gang]'s Articles
必应学术
必应学术Similar articles in
[Zhou, Junhua]'s Articles
[Zhang, Yimiao]'s Articles
[Liu, Gang]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.